Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT05790213
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Androgen Deprivation Therapy (ADT) — DRUG
    ADT will be given for 3 months. Participants will receive a standard ADT as chosen by their study doctor.
  • Focal prostate ablation (focal therapy) — PROCEDURE
    Focal prostate ablation (focal therapy) is a surgical procedure to destroy cancer cells by destroying a portion of the prostate instead of the whole prostate.

Study Details

The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).

Key Dates

Start date
May 5, 2025
Status verified
May 2025
Primary completion
Dec 18, 2028
Completion
Dec 18, 2028

Study Design

Enrollment
57 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm
    Participants will receive Androgen deprivation therapy (ADT) followed by Focal prostate ablation (focal therapy)

Primary Outcome Measure

Number of participants with clinically significant residual prostate cancer in ablated prostate tissue following study treatment [ Time Frame: End of Treatment (approximately 4-5 months) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UChicago Medicine Comprehensive Cancer CenterChicagoIllinois60637
Cancer Intake
[email protected]
855-702-8222
Abhinav Sidana, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
UChicago Medicine Comprehensive Cancer Center· Chicago, IL

Related Studies